Steady-State pharmacokinetics and tolerability of Indinavir-Lopinavir/R Combination therapy in Antiretroviral-experienced patients
Antoniou, T., Tseng, A.L., van Heeswijk, R.P.G., Walker, S.E., Giquere, P. and Phillips, E.J. (2005) Steady-State pharmacokinetics and tolerability of Indinavir-Lopinavir/R Combination therapy in Antiretroviral-experienced patients. Therapeutic Drug Monitoring, 27 (6). pp. 779-781.
*Subscription may be required
Six HIV-positive antiretroviral experienced patients initiating therapy with a regimen including lopinavir/ritonavir (400/100 mg twice per day) and indinavir (800 mg twice per day) underwent steady-state pharmacokinetic analysis. The AUC0-12h of indinavir when combined with lopinavir/ritonavir was comparable with previously published data on indinavir/ritonavir 800/100 mg twice per day in HIV-infected individuals. However, lopinavir AUC0-12h, Cmax, and C12h were lower than previously reported in the absence of indinavir. The regimen was well tolerated, although 2 patients developed grade 3 hypertriglyceridemia. No patient discontinued the regimen because of indinavir-related urologic or retinoid-type adverse effects. Further study of the regimen with larger cohorts of patients is necessary.
|Publication Type:||Journal Article|
|Publisher:||Lippincott Williams & Wilkins|
|Copyright:||© 2005 Lippincott Williams & Wilkins, Inc.|
|Item Control Page|